Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618449 · ClinicalTrials.gov registry record · Phase 4
Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger
A Phase 4 study of Trachoma and Chlamydia Trachomatis, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,139
- Enrollment target
- 2
- Study locations
NCT00618449: Completed Phase 4 study of Trachoma and Chlamydia Trachomatis, sponsored by University of California, San Francisco.
NCT00618449 is a Phase 4 study of Trachoma and Chlamydia Trachomatis that has completed, run by University of California, San Francisco. The registered enrollment target is 1,139 participants, below the 80,281-participant average among 4 other Trachoma trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00618449, a Phase 4 study of Trachoma and Chlamydia Trachomatis, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,139 participants
- Enrollment target
- 2
- Study locations
Study Summary
Trachoma is a disease of poverty, which in the hyperendemic areas affects all individuals by the time they are two years old. Active disease is concentrated in children and occurs sporadically in adults. Infection is more widespread. It is anticipated that 25% of the children will be blinded by this disease if they live to be 60 years of age. The blindness rates are higher in women, presumably because of their closer contact with children who can infect them and add to damage from infections the women had while young. This proposal is to better define how azithromycin in community-based treatment can be used to eliminate blinding trachoma. We will also take the opportunity to join these field studies with genetic epidemiologic studies to better understand the dynamic epidemiology of Chlamydia trachomatis infection in a trachoma endemic area. The empiric data generated from the treatment/follow-up studies, together with the information on sources and spread patterns from genetic epidemiology will be used to generate more robust models to guide future treatment/re-treatment protocols. We propose to conduct a randomized, community based trial in the Maradi region of Niger to test the hypothesis that two community wide azithromycin treatments, spaced one month apart, are significantly more effective in reducing ocular C. trachomatis infection and trachoma at one year compared to a single mass azithromycin treatment.
Conditions Studied
Interventions
- DRUG Azithromycin
- DRUG Azithromcyin
Study Locations (2)
California
- Chlamydia Research Laboratory - San Francisco
Other
- Programme National de Lutte Contre la Cécité - Niamey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,139 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-08 |
| Phase | Phase 4 |
What the finished NCT00618449 record still lists
NCT00618449 is an interventional study that assigns participants to a tested intervention. Its 1,139 participants enrollment target places it among the larger protocols in the corpus, below the 80,281-participant average among 4 other Trachoma trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Trachoma appearing as the primary indexed condition, and to 2 interventions - of which Azithromycin is the first listed.
NCT00618449 reports a single indexed study location in California, Other.
Frequently Asked Questions
What is clinical trial NCT00618449 about?
NCT00618449 is a clinical study titled "Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger". Trachoma is a disease of poverty, which in the hyperendemic areas affects all individuals by the time they are two years old. Active disease is concentrated in children and occurs sporadically in adults. Infection is more widespread. It is anticipated that 25% of the children will be blinded by this...
What is the current status of trial NCT00618449?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,139 participants. The study started on 2008-01. Estimated completion is 2009-08.
What conditions does trial NCT00618449 study?
This clinical trial studies the following conditions: Trachoma, Chlamydia Trachomatis.
What interventions are being tested in trial NCT00618449?
The interventions under investigation include: Azithromycin (DRUG), Azithromcyin (DRUG).
Who is sponsoring clinical trial NCT00618449?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00618449 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Trachoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Kebele Elimination of Trachoma for Ocular Health
ACTIVE NOT RECRUITING · Phase 4
-
Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania
COMPLETED · Phase 4
-
Impact of Water and Health Education Programs on Trachoma and Ocular C. Trachomatis in Niger
COMPLETED · Phase 4
-
A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05894967 · 1,140 participants · NA
Moderators and Mediators of Perceptual Learning
- NCT06532487 · 1,140 participants · NA
Addressing Durable Health Disparities Through Critical Time Legal Interventions in Medically Underserved Latinx and Migrant Communities
- NCT06129864 · 1,145 participants · Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- NCT06676319 · 1,147 participants · Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia